

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 370175 **Equazen Capsules**

ARTG entry for Medicine Listed

Sponsor SFI Australasia

Postal Address PO Box 1027, CROWS NEST, NSW, 1585

24/06/2021 ARTG Start Date **Product Category** Medicine Status Active

Listed Medicines Approval Area

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Equazen Capsules

Product Type Effective Date 24/06/2021 Single Medicine Product

Permitted Indications

Maintain/support healthy eye function

Maintain/support healthy eye function in children

Maintain/support eye health

Helps maintain/support healthy vision development in children

Maintain/support general health and wellbeing

Helps enhance/improve/promote/increase attention span in children

Maintain/support cognitive development in children

Maintain/support mental concentration/focus/clarity in children

Enhance/improve/promote/increase cognitive performance in children

Maintain/support cognitive function/mental function in children

Maintain/support cognitive function/mental function

Maintain/support learning and information processing in children

Enhance/improve/promote learning ability/function in children

Maintain/support memory/mental recall in children

Maintain/support brain function in children

Maintain/support brain function

Maintain/support brain/central nervous system development in children

Indication Requirements

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to neurological conditions or developmental delays.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Page 1 of 2



Australian Government

Department of Health

Therapeutic Goods Administration

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, soft

Route of Administration Oral

Visual Identification

Active Ingredients

concentrated fish Omega-3 triglycerides 155 mg
Evening Primrose Oil 100 mg

Other Ingredients (Excipients)

d-alpha-tocopherol

Gelatin

glycerol

purified water

Soya Oil

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.